Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 21,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Low Back Pain
Interventions: ED Physical Therapy; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions: Aquamantys, standard electrocautery (Bovie); Device
Lead sponsor: Joint Implant Surgeons, Inc.; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: AZD4512, Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more

Conditions: Neuromyelitis Optica
Interventions: High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions: Concept Elicitation, Comprehension Assessment; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New York, New York + 1 more

Conditions: HIV Infections
Interventions: Text messaging plus EMA, Treatment as usual; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Walking Impairment, Multiple Sclerosis
Interventions: ADS-5102, Placebo; Drug · Other
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Aurora, Colorado • Sarasota, Florida + 12 more

Conditions: Influenza, Human, Human Immunodeficiency Virus I Infection
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib; Drug
Lead sponsor: Ajai Chari; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: megadose oral methylprednisolone, IV methylprednisolone; Drug
Lead sponsor: Fred Lublin; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 10
States / cities: New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more

Conditions: HIV/AIDS, Substance Abuse
Interventions: Directly Administered Antiretroviral Therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: Thalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Alcohol Drinking, Chronic Inflammation, Neurocognitive Dysfunction, Liver Diseases, HIV Infections
Interventions: Contingency Management (CM); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes
Interventions: Lantus and short acting analogs Vs NPH and short acting analogs; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Autoimmune
Interventions: DiaPep277; Drug
Lead sponsor: DeveloGen Israel, Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more

Conditions: Hiv, Sexually Transmitted Diseases, Aging
Interventions: safe sex and HIV/STD prevention education via a website, written materials on safe sex; Behavioral · Other
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions: tanespimycin, bortezomib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Miami, Florida • Albany, New York • Stony Brook, New York

Conditions: Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Interventions: PRT1419, Azacitidine, Venetoclax; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Stamford, Connecticut • Miami, Florida • Pembroke Pines, Florida + 3 more

Conditions: Multiple Myeloma
Interventions: AEVI-007; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Sacramento, California • West Hollywood, California • Lake Mary, Florida + 4 more

Conditions: Asthma
Interventions: Achipex; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lymphoma
Interventions: arsenic trioxide; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Type 1 Diabetes
Interventions: HIGH error, NO error, LOW error; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

ED Physical Therapy for Chronic Low Back Pain

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions

Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Directly Observed Antiretroviral Therapy Among Active Drug Users

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma

30-to-90 Day Challenge: Effects of Alcohol Cessation on Health Outcomes

Lantus in the Treatment of Type 1 Diabetes Children

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Prevention of HIV/AIDS and STDs in Women Over Fifty

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

The Role of GER in Exercise Triggered Asthma

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

Effect of Gain on Closed-Loop Insulin